<DOC>
	<DOCNO>NCT01141270</DOCNO>
	<brief_summary>Comparative pharmacokinetics study single subcutaneous application AFOLIA reference product ( Gonal-f® ) . Objective : To demonstrate equivalence within 80 % -125 % margin reference product area curve ( AUC ) AFOLIA compare ( Gonal-f® ) .</brief_summary>
	<brief_title>Comparative Pharmacokinetics AFOLIA Gonal-f® After Single Subcutaneous Application</brief_title>
	<detailed_description />
	<criteria>Healthy female volunteer Age 1838 year Body mass index 1729 kg/m2 Woman child bear potential must agree practice effective barrier method birth control Use oral contraceptive least 3 month study entry Regular menstruation cycle ( 2534 day ) initiation oral contraception Presence ovaries Normal finding medical history physical gynaecological examination unless investigator considers abnormality clinically irrelevant study Signed informed consent Polycystic ovary syndrome ( PCOS ) History hypersensitivity FSH ( Ovary Hyperstimulation Syndrome , OHSS ) Impaired thyroid function ( treat untreated ) History malignant disease AST and/or ALAT &gt; 2 x ULN Other clinically relevant finding ( ECG , blood pressure , physical , gynecological examination , laboratory examination ) Smoking habit 5 cigarette per day Abuse alcoholic beverage drug Participation clinical trial within 3 week prior study Foreseen inability attend schedule study visit Symptoms clinically relevant illness 3 week prior first study day Pregnancy lactation period Any medical condition , opinion investigator , would interfere safety subject interference objective study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>38 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>recombinant human follicle stimulate hormone</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>bioequivalence</keyword>
</DOC>